Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - amoxicillin as trihydrate; clavulanic acid as potassium salt - film coated tablets - amoxicillin as trihydrate 250 mg; clavulanic acid as potassium salt 125 mg - amoxicillin and enzyme inhibitor - amoxicillin and enzyme inhibitor - augmentin is indicated for the treatment of the following infections in adults and children :• acute bacterial sinusitis (adequately diagnosed)• otitis media infection• acute pharyngitis• cystitis• pyelonephritis• skin and soft tissue infections in particular cellulitis, animal bites, severe dental abscess with spreading cellulitis.

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - amoxicillin as trihydrate; clavulanic acid as potassium salt - powder for suspension - clavulanic acid as potassium salt 57 mg / 5 ml; amoxicillin as trihydrate 400 mg / 5 ml - amoxicillin and enzyme inhibitor - amoxicillin and enzyme inhibitor - augmentin is indicated for the treatment of the following infections in adults and children: • acute bacterial sinusitis (adequately diagnosed)• acute otitis media• acute exacerbations of chronic bronchitis (adequately diagnosed)• community acquired pneumonia• cystitis• pyelonephritis• skin and soft tissue infections in particular cellulitis, animal bites, severe dental abscess with spreading cellulitis.• bone and joint infections, in particular osteomyelitis.• recurrent tonsillitis

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - amoxicillin as trihydrate; clavulanic acid as potassium salt - powder for suspension - clavulanic acid as potassium salt 11.4 mg/ml; amoxicillin as trihydrate 80 mg/ml - amoxicillin and enzyme inhibitor - augmentin is indicated for the treatment of the following infections in adults and children: • acute bacterial sinusitis (adequately diagnosed)• acute otitis media• acute exacerbations of chronic bronchitis (adequately diagnosed)• community acquired pneumonia• cystitis• pyelonephritis• skin and soft tissue infections in particular cellulitis, animal bites, severe dental abscess with spreading cellulitis.• bone and joint infections, in particular osteomyelitis.• recurrent tonsillitis

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - amoxicillin as trihydrate; clavulanic acid as potassium salt - film coated tablets - amoxicillin as trihydrate 875 mg; clavulanic acid as potassium salt 125 mg - ampicillin and enzyme inhibitor - augmentin is indicated for the treatment of the following infections in adults and children :• acute bacterial sinusitis (adequately diagnosed)• acute otitis media• acute exacerbations of chronic bronchitis (adequately diagnosed)• community acquired pneumonia• cystitis• pyelonephritis• skin and soft tissue infections in particular cellulitis, animal bites, severe dental abscess with spreading cellulitis.• bone and joint infections, in particular osteomyelitis.

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - amoxicillin trihydrate 28.698 mg/ml equivalent to amoxycillin 25mg/ml; potassium clavulanate 7.446 mg/ml equivalent to clavulanic acid 6.25mg/ml - powder for oral suspension - 125 mg/5ml - active: amoxicillin trihydrate 28.698 mg/ml equivalent to amoxycillin 25mg/ml potassium clavulanate 7.446 mg/ml equivalent to clavulanic acid 6.25mg/ml excipient: aspartame colloidal silicon dioxide golden syrup flavour 52927 ap0551 hydrated silica hypromellose orange flavour phs-134215 orange flavour sd653970 raspberry flavour nn07943 succinic acid xanthan gum - augmentin should be used in accordance with local official antibiotic prescribing guidelines and local susceptibility data. augmentin is indicated for the short term treatment of common bacterial infections in adults and children such as: upper respiratory tract infections (including ent): e.g. tonsillitis, sinusitis, otitis media lower respiratory tract infections: e.g. acute exacerbations of chronic bronchitis, lobar and broncho pneumonia genito-urinary tract infections: e.g. cystitis, urethritis, pyelonephritis, female genital infections skin and soft tissue infections bone and joint infections: e.g. osteomyelitis other infections: e.g. septic abortion, puerperal sepsis, intra-abdominal sepsis, septicaemia, peritonitis, post-surgical infections susceptibility to augmentin will vary with geography and time. local susceptibility data should be consulted where available, and microbiological sampling and susceptibility testing performed where necessary. infections caused by amoxicillin susceptible organisms are amenable to augmentin treatment due to its amoxicillin content. mixed infections caused by amoxicillin susceptible organism in conjunction with augmentin susceptible beta-lactamase-producing organisms may therefore be treated by augmentin.

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - amoxicillin trihydrate 57.394 mg/ml equivalent to amoxycillin 50mg/ml; potassium clavulanate 14.89 mg/ml equivalent to clavulanic acid 12.5mg/ml - powder for oral suspension - 250 mg/5ml - active: amoxicillin trihydrate 57.394 mg/ml equivalent to amoxycillin 50mg/ml potassium clavulanate 14.89 mg/ml equivalent to clavulanic acid 12.5mg/ml excipient: aspartame colloidal silicon dioxide golden syrup flavour 52927 ap0551 hydrated silica hypromellose orange flavour phs-134215 orange flavour sd653970 raspberry flavour nn07943 succinic acid xanthan gum - augmentin should be used in accordance with local official antibiotic prescribing guidelines and local susceptibility data. augmentin is indicated for the short term treatment of common bacterial infections in adults and children such as: upper respiratory tract infections (including ent): e.g. tonsillitis, sinusitis, otitis media lower respiratory tract infections: e.g. acute exacerbations of chronic bronchitis, lobar and broncho pneumonia genito-urinary tract infections: e.g. cystitis, urethritis, pyelonephritis, female genital infections skin and soft tissue infections bone and joint infections: e.g. osteomyelitis other infections: e.g. septic abortion, puerperal sepsis, intra-abdominal sepsis, septicaemia, peritonitis, post-surgical infections susceptibility to augmentin will vary with geography and time. local susceptibility data should be consulted where available, and microbiological sampling and susceptibility testing performed where necessary. infections caused by amoxicillin susceptible organisms are amenable to augmentin treatment due to its amoxicillin content. mixed infections caused by amoxicillin susceptible organism in conjunction with augmentin susceptible beta-lactamase-producing organisms may therefore be treated by augmentin.

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - amoxicillin trihydrate 573.96mg equivalent to amoxicillin 500 mg;  ; potassium clavulanate 148.91mg equivalent to clavulanic acid 125 mg;   - film coated tablet - 500mg/125mg - active: amoxicillin trihydrate 573.96mg equivalent to amoxicillin 500 mg   potassium clavulanate 148.91mg equivalent to clavulanic acid 125 mg   excipient: colloidal silicon dioxide dimeticone hypromellose macrogol 4000 macrogol 6000 magnesium stearate microcrystalline cellulose opadry white oy-s-7300 as an alternative source of film coat sodium starch glycolate titanium dioxide - augmentin should be used in accordance with local official antibiotic prescribing guidelines and local susceptibility data. augmentin is indicated for the short term treatment of common bacterial infections in adults and children such as: upper respiratory tract infections (including ent): e.g. tonsillitis, sinusitis, otitis media lower respiratory tract infections: e.g. acute exacerbations of chronic bronchitis, lobar and broncho pneumonia genito-urinary tract infections: e.g. cystitis, urethritis, pyelonephritis, female genital infections skin and soft tissue infections bone and joint infections: e.g. osteomyelitis other infections: e.g. septic abortion, puerperal sepsis, intra-abdominal sepsis, septicaemia, peritonitis, post-surgical infections susceptibility to augmentin will vary with geography and time. local susceptibility data should be consulted where available, and microbiological sampling and susceptibility testing performed where necessary. infections caused by amoxicillin susceptible organisms are amenable to augmentin treatment due to its amoxicillin content. mixed infections caused by amoxicillin susceptible organism in conjunction with augmentin susceptible beta-lactamase-producing organisms may therefore be treated by augmentin.

United States - English - NLM (National Library of Medicine)

allegis pharmaceuticals, llc - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9), clavulanate potassium (unii: q42omw3at8) (clavulanic acid - unii:23521w1s24) - augmentin is indicated for the treatment of infections in adults and pediatric patients, due to susceptible isolates of the designated bacteria in the conditions listed below: - lower respiratory tract infections - caused by beta‑lactamase–producing isolates of haemophilus influenzae and moraxella catarrhalis . - acute bacterial otitis media - caused by beta‑lactamase–producing isolates of h. influenzae and m. catarrhalis . - sinusitis - caused by beta‑lactamase–producing isolates of h. influenzae and m. catarrhalis . - skin and skin structure infections - caused by beta‑lactamase–producing isolates of staphylococcus aureus , escherichia coli , and klebsiella species. - urinary tract infections - caused by beta‑lactamase–producing isolates of e. coli , klebsiella species, and enterobacter species. limitations of use when susceptibility test results show susceptibility to amoxicillin, indicating no beta-lactamase production, augmentin should not b

United States - English - NLM (National Library of Medicine)

dr reddys laboratories inc - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9), clavulanate potassium (unii: q42omw3at8) (clavulanic acid - unii:23521w1s24) - amoxicillin anhydrous 600 mg in 5 ml - augmentin es-600 powder for oral suspension is indicated for the treatment of pediatric patients with recurrent or persistent acute otitis media due to s. pneumoniae (penicillin mics ≤ 2 mcg/ml), h. influenzae (including β-lactamase–producing strains), or m. catarrhalis (including β-lactamase–producing strains) characterized by the following risk factors: - antibiotic exposure for acute otitis media within the preceding 3 months, and either of the following: age ≤ 2 years daycare attendance - age ≤ 2 years - daycare attendance [see clinical pharmacology, microbiology.] note: acute otitis media due to s. pneumoniae alone can be treated with amoxicillin. augmentin es-600 powder for oral suspension is not indicated for the treatment of acute otitis media due to s. pneumoniae with penicillin mic ≥ 4 mcg/ml. therapy may be instituted prior to obtaining the

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - amoxicillin as trihydrate; clavulanic acid as potassium salt - film coated tablets - amoxicillin as trihydrate 500 mg; clavulanic acid as potassium salt 125 mg - amoxicillin and enzyme inhibitor - amoxicillin and enzyme inhibitor - augmentin is indicated for the treatment of the following infections in adults and children :• acute bacterial sinusitis (adequately diagnosed)• acute otitis media • acute exacerbations of chronic bronchitis (adequately diagnosed)• community acquired pneumonia• cystitis• pyelonephritis• skin and soft tissue infections in particular cellulitis, animal bites, severe dental abscess with spreading cellulitis.• bone and joint infections, in particular osteomyelitis.